Essential principles towards improving clinical risk assessment tools: A conversation with Uri Kartoun, PhD

Abstract

Uri Kartoun (PhD in robotics, Ben Gurion University of the Negev, Israel) is a Staff Research Scientist and an IBM Master Inventor, co-developer of technologies such as MELD-Plus, EMRBots, Memory-memory (M2) Authentication, and Subpopulation-based Feature Selection. Prior to joining IBM Research in 2016, Kartoun worked at Microsoft Health Solutions Group and at Massachusetts General Hospital. EMWA Guest Editor Daniela Kamir, PhD, interviewed Kartoun about clinical risk assessment tools, organ transplant allocation disparities, and how the Model for End-Stage Liver Disease (MELD) score is used to allocate livers for transplantation. The conversation has been edited for brevity and clarity.